Love this slide depicting anti-PF4 disorders #isth2024

Fantastic 1st AAACTT meeting in مؤسسة ومركز الحسين للسرطان in Amman, Jordan. Outstanding talks with full house and super-delicious “mansaf” Amer Zeidan MBBS,MHS ‏عامر زيدان (will be jealous)! Thank you, Chris Kanakry, Ramzi Abboud, Kamil R, khalid A. Halahleh Zaid Abdel-Rahman Hasan Hashem Mohamed Kharfan-Dabaja, MD, MBA @usamagergis Muna Qayed

As a scientific committee reviewer of the 2nd مؤسسة ومركز الحسين للسرطان research meeting under the patronage of HRH Princess Ghida Talal , it is very gratifying to see this large number of high quality research projects & reflecting the status of KHCC as the best cancer center in the Middle East

New in NEJM: 7/67 pts who received eli-cel developed heme malignancies, all MDS or AML. All cases were d/t clonal vector insertions in MECOM or PRDM16 (great longitudinal figure). #celltherapy #leusm

Yet another failed randomized trial of HMA combination in higher risk #MDSsm, this time with RARA agonist tamibarotene: n=245, CR rate 23.8% with combo vs 18.8% HMA alone, p=0.20. This is becoming a depressing and recurring theme, Amer Zeidan MBBS,MHS ‏عامر زيدان. ir.syros.com/press-releases…

A Samer Al-Homsi Potential game changer for #GVHD prophylaxis with #CAST = PTCy, abatacept, and short course tacrolimus A Samer Al-Homsi "Do not cut the dose of PTCy outside of trials" in Re-CAST study, higher rates of cGVHD observed:

#mmsm #ASH24 ASH Excellent work from Dr Abeer Yaseen Zaid Abdel-Rahman مؤسسة ومركز الحسين للسرطان on outcomes of MM treated in Jordan Stop at 2277 to check it out Hope this will be published soon #ASHKudos

مؤسسة ومركز الحسين للسرطان team attending #ASH24 !

Honored to present the James D. Cook, M.D. Memorial Lecture on MDS at the KansasUniversity #ASH24 Review. Grateful for the invitation and Dr. Abdulraheem Yacoub's inspiring opening remarks. Let the learning begin! 🎊🎊 UT Southwestern Medical Center UTSW Simmons Cancer Center

.KU Cancer Center’s Dr. Anurag Singh (Anurag Singh) and Dr. Zaid Abdel Rahman (Zaid Abdel-Rahman) from مؤسسة ومركز الحسين للسرطان are co-presenting “Approach to Hereditary Hematologic Malignancies and Inherited Bone Marrow Failure Syndromes” at #kuASHreview. #KUBloodCancer

Fantastic talk by Jacob Cogan on thrombosis updates at #ASH24 University of Kansas review event!! The #Arabic touch with #حبة_ملح (pinch of salt) =myView in the slides ;)👏🎉 Abdulraheem Yacoub Zaid Abdel-Rahman

Phenomenal talk by Zaid Abdel-Rahman on hereditary hematologic malignancies—an inspiring approach to global collaboration, bridging continents with impactful efforts Cancer Center (KHCC) & KU Cancer Center. 🍻 to advancing care worldwide! #GlobalOncology #HemeMalignancies

Excellent talk on Advances in MDS by Yazan Madanat, MD at KU Cancer Center's #kuASHreview #ASH24

Thrilled to present the MDS #ASH24 updates at the KU Cancer Center University of Kansas Annual Review and reconnect with incredible colleagues like Zaid Abdel-Rahman and Abdulraheem Yacoub! 🎉 Such a fantastic event filled with inspiration and #collaboration! #MDSsm #MPNsm

I had the incredible privilege of presenting some of the work we've done مؤسسة ومركز الحسين للسرطان at Mayo Clinic Comprehensive Cancer Center in Florida, the place that shaped me as a physician and a person. To my mentors and colleagues: thank you for a wonderful time and I hope to see you in the near future.

Privileged to present some of the work we’ve done at King Hussein Cancer Foundation - Zaid Abdel-Rahman مؤسسة ومركز الحسين للسرطان Mayo Clinic Comprehensive Cancer Center oncodaily.com/blog/229429 #Cancer #OncoDaily #MedEd #MedX #MedNews #Medicine #Oncology

Association between Wealth and Mortality in the United States and Europe | ⁦NEJM⁩ “Survival in the wealthiest U.S. quartile appeared to be similar to that in the poorest quartile in northern and Western Europe” nejm.org/doi/full/10.10…

Our report on olutasidenib for patients with IDH1 mutated AML arising from MPN has been published. Georgia Cancer Center MPN_Hub onlinelibrary.wiley.com/doi/10.1111/bj…

👉👉 Happy to share results of investigator initiated trial of Ruxolitinib in Ph-Like ALL. We did not see any significant responses in R/R adult Ph-like B-ALL with ruxolitinib. 👉Looking back at my emails Marina Konopleva and I had initial discussions with Incyte for this trial at ASH

With the disappointing announcement today by AbbVie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1